Quote, "Aren't we supposed to be partnering with someone and not buying someone else's technology?
"
EXACTLY ! So ole supposed miracle workers OCAT, the greatest supposed gift to medicine in the past 100 yrs- doesn't actually invent their own tech, but went and PAID and/or WILL PAY a licensing fee to some micro sized outfit in San Diego who can produce the goods they can't?
What? I thought ole OCAT was the genius center of planet earth according to folk lore and myths? And this tech they just licensed - it's "lab level", so once again, how many years and years away is that from some FDA shot at approval, etc?
Is this the mythological "partnership", a licensing deal where OCAT is footing the bill to someone else, LOL?
Further, look at the wording in the OCAT PR; all they claim to "have" at this point regarding the supposed "cure" to blindness that is so often spoken of in mythology land- is a "proof of concept" and ANIMAL MODELS? What? I thought this was a DONE DEAL and like 6 months away from flying off the shelves of the local doctor's office and all? "proof of concept" and ANIMAL TESTING? That's about as early a phase/stage of development a medical DRUG can be in? YEARS to FDA or similar approvals- if ever.
Quote:
""This agreement with Allele is part of our strategy to broaden our technology platform and increase our leadership in regenerative ophthalmology,” said Paul Wotton Ph.D., President and CEO of Ocata. “Ocata can now take advantage of induced and embryonic pluripotent stem cells to produce commercially viable human tissue for transplantation. We recently confirmed proof of concept in creating photoreceptors capable of preventing blindness and restoring vision in established animal models. Data from these studies will be published later this year.”"
Also, that PR is loaded with the ole "potential" and other similar wording- meaning it's not even a 100% sure thing, not even proven technology per their wording:
Quote:
"Despite many efforts to develop iPSC derived therapies in the same scalable and reliable way as embryonic stem cells, many of those efforts have been unsuccessful due to issues relating to the growth capacity, differentiation potentials and epigenetic properties of iPSCs. The “footprint-free” reprogramming technology developed by Allele potentially offers a reliable and scalable process for producing iPSCs with superior properties and is a major step for translation of iPSC technology to practical clinical use. These iPSCs can potentially be used to manufacture millions of treatment doses as off-the-shelf therapies for any patient."
Also, WHERE'S THE FINANCIAL TERMS of this "agreement" and all the other missing details? Is it, will it be an an exclusive license? How much is cash-low OCAT paying, how often and for how long, etc? SWISS CHEESE PR it's so full of holes and missing critical info IMO. Pure fluff and not much substance to exlain anything in that ole PR IMO. It really only says "agreement" which technically isn't even a "license" IMO, and certainly not an exclusive license- which means competitors and others could be using the same technology w/o any conflict of interest, license/patent violations, etc.
